Tumor-derived organoids (TDOs) have been initially generated from normal organoids by introducing pro-tumorigenic mutations, such as the losses of APC and TP53 [75,76], and then directly from fresh tumor specimens, which capture the cellular and molecular diversity of the clinical samples [77,78,79,80,81,82]. The gene discussed is TP53; the disease is neoplasm.